23 min listen
Gemini CEO McLaughlin Explains How the Precision Therapeutics Start-up Will Take Aim at Eye Disease
Gemini CEO McLaughlin Explains How the Precision Therapeutics Start-up Will Take Aim at Eye Disease
ratings:
Length:
20 minutes
Released:
Oct 18, 2017
Format:
Podcast episode
Description
Ophthalmology companies have had a difficult time targeting AMD lately. Newcomer Gemini Therapeutics is bringing a “multimodal approach” to identify new targets in the complement system, with an eye toward developing specific treatments for patients with connected genetic codes. CEO, president, and co-founder James McLaughlin explains how Gemini hopes to advance the war against these dreadful diseases.
Released:
Oct 18, 2017
Format:
Podcast episode
Titles in the series (100)
Lindstrom: Ophthalmologists Facing Both Opportunity And Pressure by OIS Podcast | Ophthalmology's leading Podcast